Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Study of teriflunomide in reducing the frequency of relapses and accumulation of disability in patients with multiple sclerosis (TEMSO)
Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial.
FDA Drug Safety Communication: FDA warns about case of rare brain infection PML with MS drug Tecfidera (dimethyl fumarate)
Evaluation of pattern-reversal visual evoked potential in patients with neuromyelitis optica.
Sex differences in comorbidity at diagnosis of multiple sclerosis: A population-based study.
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.
Reversible cerebral vasoconstriction syndrome associated with interferon beta-1a use for multiple sclerosis.
Multiple sclerosis: A lifestyle disease?
Interferon beta-1a long-term therapy related to pulmonary arterial hypertension in multiple sclerosis patients.
Information for healthcare professionals: Rituximab
Ampyra (dalfampridine)
Remote Physical Activity Monitoring in Neurological Disease: A Systematic Review.
Rapid exacerbation of neuromyelitis optica after rituximab treatment.
Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.
KIR2DL2 inhibitory pathway enhances Th17 cytokine secretion by NK cells in response to herpesvirus infection in multiple sclerosis patients.
Comparison of the Effects of Matrix Metalloproteinase Inhibitors on TNF-α Release from Activated Microglia and TNF-α Converting Enzyme Activity.
IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS.
Individualized quality of life of severely affected multiple sclerosis patients: practicability and value in comparison with standard inventories.
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.
Genzyme Announces EMA Accepts Oral Teriflunomide Marketing Application for Treatment of Multiple Sclerosis
Interferon-β-1b: a review of its use in multiple sclerosis.
A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis.
Acute transverse myelitis: demyelinating, inflammatory, and infectious myelopathies.
Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy.

Pages